Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SCIO Scios Inc. -- Ignore unavailable to you. Want to Upgrade?

To: Casaubon who wrote (1467)	2/8/2003 9:57:17 PM
From: Miljenko Zuanic	Respond to of 1477

I will continue to believe, until proven opposite, that 496 is not right molecule “”Can you point me to some of your reasons? Also, have you chosen a horse to bet on, in the P38 race? “” Relative large doses in animal model to generate drug effects. Side effects at single higher doses, no data from PIb trials, safety PIb dose increase in combination with MTX,… All this does not sound like strait forward clinical path. More likely they are testing p38 path and still without proof of concept. Even VRTX turned away from chronic RA and refocus toward cardiovascular ACS setting. No favorite from P38, no bet at all. Miljenko